“Hodgkin lymphoma in adults is a disease in which cancer cells form in the lymph system, part of the body’s immune system. Because lymph tissue is found throughout the body, Hodgkin lymphoma can begin in almost any part of the body and spread to almost any tissue or organ in the body.
Lymphomas are divided into two general types: Hodgkin lymphoma and non-Hodgkin lymphoma.
Hodgkin lymphoma can occur in both adults and children. Hodgkin lymphoma may also occur in patients who have acquired immunodeficiency syndrome (AIDS); these patients require special treatment.
An estimated 8,830 people will be diagnosed with Hodgkin lymphoma and 900 people will die of the disease in 2023, according to the National Cancer Institute (NCI). The NCI estimates that more than 75 percent of all newly diagnosed patients with adult Hodgkin lymphoma can be cured with chemotherapy and/or radiation therapy.
There are two main types of Hodgkin lymphoma: classical and nodular lymphocyte-predominant. Most Hodgkin lymphomas are the classical type, which includes four subtypes – nodular sclerosing, mixed cellularity, lymphocyte-depleted, and lymphocyte-rich.
Risk factors for adult Hodgkin lymphoma include:
- Being in young or late adulthood.
- Being male.
- Being infected with the Epstein-Barr virus.
- Having a first-degree relative – parent, brother, or sister with Hodgkin lymphoma”
FDG PET/CT (Hodgkins Lymphoma) Visualized
National Comprehensive Cancer Network® (NCCN®) Comments on PET/CT and Hodgkin’s Lymphoma
The Role of FDG-PET Imaging in Management of Classic Hodgkin’s Lymphoma (CHL)
“FDG-PET imaging including integrated FDG-PET and CT (FDG-PET/CT) has become an important tool for initial staging and response assessment at the completion of treatment in patients with HL.12,13 In a meta-analysis, FDG-PET scans showed high positivity and specificity when used to stage and restage
patients with lymphoma.”
Interim FDG-PET Imaging NCCN comments:
“Interim FDG-PET scans can be prognostic and are increasingly being used to assess treatment response during therapy, 28,29 as they can inform treatment adaptation, including treatment escalation and de-escalation.30,31 Early interim FDG-PET imaging after chemotherapy has been shown to be a sensitive prognostic indicator of treatment outcome in patients with advanced-stage disease (stage II disease with unfavorable risk factors [with or without bulky disease] or stage III–IV disease). Interim FDGPET scans may also be useful to identify a subgroup of patients with early- and advanced-stage disease that can be treated with chemotherapy alone.”
Permission Pending from the National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hodgkin Lymphoma Version 2.2023 — November 8, 2022. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 15, 2023 To view the most recent and complete version of the guideline, go online to NCCN.org.
Source: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf (page 52/94).